0ABW.LSE Egetis Therapeutics AB
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is 0ABW.LSE undervalued?
Graham numberThe Graham number of Egetis Therapeutics AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Egetis Therapeutics AB fundamental analysis
No fundamental analysis for Egetis Therapeutics AB yet.
Egetis Therapeutics AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Egetis Therapeutics AB
Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for the treatment of monocarboxylate transporter 8 deficiency. The company was form…
Full company profileFinancial statements of Egetis Therapeutics AB are not available yet.
Egetis Therapeutics AB dividends
Egetis Therapeutics AB has not paid dividends in the last 4 fiscal years.
Who owns Egetis Therapeutics AB
- Insiders 23.39%
- Institutions 51.60%
- Public & others 25.01%
- Free float 240M
Egetis Therapeutics AB company profile
- Company name
- Egetis Therapeutics AB
- Ticker
- 0ABW.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 56
- Fiscal year end
- December
- Address
- Klara Norra Kyrkogata 26, Stockholm, Sweden, 111 22
- Phone
- 46 86 79 72 10
- Website
- egetis.com
About Egetis Therapeutics AB
Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for the treatment of monocarboxylate transporter 8 deficiency. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is headquartered in Stockholm, Sweden.
Egetis Therapeutics AB management
10- Mr. Nicklas WesterholmChief Executive Officer · born 1976
- Mr. Torsten AlménFounder
- Dr. Ingemar Lundström Ph.D.Founder · born 1943
- Dr. Louis Joseph Ignarro Ph.D.Founder · born 1942
- Associate Prof. Heidi BrurokFounder
- Dr. Rob TowartFounder
- Dr. Yilmaz Mahshid Ph.D.Chief Financial Officer · born 1979
- Dr. Katayoun Welin-Berger Ph.D.Vice President of Operations · born 1968
- Dr. Karl Hard Ph.D.Head of Investor Relations & Business Development · born 1962
- Ms. Laetitia Szaller L.L.M.General Counsel & Head of Compliance